{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:56:36Z","timestamp":1790826996050,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, Govt. of India"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ejps.2019.105048","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T11:46:35Z","timestamp":1566474395000},"page":"105048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Co amorphous valsartan nifedipine system: Preparation, characterization, in vitro and in vivo evaluation"],"prefix":"10.1016","volume":"139","author":[{"given":"Anurag","family":"Lodagekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul B.","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K. Chaitanya","family":"Mannava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balvant","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Chella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini K.","family":"Nangia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalini R.","family":"Shastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2019.105048_bb0005","first-page":"1","article-title":"Enhanced dissolution of valsartan-vanillin binary co-amorphous system loaded in mesoporous silica particles","author":"Ali","year":"2019","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejps.2019.105048_bb0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijpharm.2016.10.043","article-title":"Co amorphous systems: a product development perspective","volume":"515","author":"Chavan","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2019.105048_bb0015","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1080\/03639045.2018.1503295","article-title":"Determination of precipitation inhibitory potential of polymers from amorphous solid dispersions","volume":"44","author":"Chavan","year":"2018","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2019.105048_bb0020","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s13318-015-0290-5","article-title":"Formulation and pharmacokinetic evaluation of polymeric dispersions containing valsartan","volume":"41","author":"Chella","year":"2016","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2019.105048_bb0025","first-page":"1","article-title":"Physico-chemical characterisation of three-component co-amorphous systems generated by a melt-quench method","author":"D'Angelo","year":"2018","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.ejps.2019.105048_bb0030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejpb.2014.12.025","article-title":"Fabrication, solid state characterization and bioavailability assessment of stable binary amorphous phases of ritonavir with quercetin","volume":"89","author":"Dengale","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2019.105048_bb0035","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.addr.2015.12.009","article-title":"Recent advances in co-amorphous drug formulations","volume":"100","author":"Dengale","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2019.105048_bb0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijpharm.2017.10.049","article-title":"The natural bile acid surfactant sodium taurocholate (NaTC) as a coformer in coamorphous systems: enhanced physical stability and dissolution behavior of coamorphous drug-NaTc systems","volume":"535","author":"Gniado","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2019.105048_bb0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/jps.21072","article-title":"Drug\u2013polymer interaction and its significance on the physical stability of nifedipine amorphous dispersion in microparticles of an ammonio methacrylate copolymer and ethylcellulose binary blend","volume":"97","author":"Huang","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105048_bb0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/10837450.2016.1163390","article-title":"Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan","volume":"22","author":"Huang","year":"2017","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejps.2019.105048_bb0055","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejpb.2018.09.024","article-title":"In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine","volume":"132","author":"Kasten","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2019.105048_bb0060","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.5114\/aoms.2018.77561","article-title":"Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis","volume":"14","author":"Kawalec","year":"2018","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.ejps.2019.105048_bb0065","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1021\/acs.molpharmaceut.5b00334","article-title":"Molecular dynamics and physical stability of coamorphous ezetimib and indapamide mixtures","volume":"12","author":"Knapik","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2019.105048_bb0075","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1021\/acs.molpharmaceut.8b00308","article-title":"Co-stabilization of amorphous pharmaceuticals\u2014the case of nifedipine and nimodipine","volume":"15","author":"Knapik-Kowalczuk","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2019.105048_bb0080","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1039\/C4CE02164A","article-title":"Effect of HPMC concentration on crystal habit of nifedipine","volume":"17","author":"Kumar","year":"2015","journal-title":"CrystEngComm"},{"key":"10.1016\/j.ejps.2019.105048_bb0085","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0032-3861(97)00371-6","article-title":"Hydrogen bonds in poly (methyl methacrylate)-poly (4-vinyl phenol) blends: 1. Quantitative analysis using FTi. r. spectroscopy","volume":"39","author":"Li","year":"1998","journal-title":"Polymer"},{"key":"10.1016\/j.ejps.2019.105048_bb0090","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1021\/acs.cgd.8b00081","article-title":"Role of valsartan as an antiplasticizer in development of therapeutically viable drug\u2013drug coamorphous system","volume":"18","author":"Lodagekar","year":"2018","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejps.2019.105048_bb0095","first-page":"1462","volume":"28","author":"Mancia","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejps.2019.105048_bb0100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/08037051.2013.812549","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"22","author":"Mancia","year":"2013","journal-title":"Blood Press."},{"key":"10.1016\/j.ejps.2019.105048_bb0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/pharmaceutics10010007","article-title":"Curcumin-artemisinin coamorphous solid: xenograft model preclinical study","volume":"10","author":"Mannava","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2019.105048_bb0110","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3390\/molecules23092161","article-title":"Co-amorphous simvastatin-nifedipine with enhanced solubility for possible use in combination therapy of hypertension and hypercholesterolemia","volume":"23","author":"Mart\u00ednez-Jim\u00e9nez","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2019.105048_bb0115","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ijpharm.2017.09.020","article-title":"Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling: enhanced physical stability, dissolution and pharmacokinetic profile","volume":"532","author":"Moinuddin","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2019.105048_bb0120","doi-asserted-by":"crossref","first-page":"104947","DOI":"10.1016\/j.ejps.2019.06.001","article-title":"How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions","volume":"136","author":"Pacu\u0142t","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105048_bb0125","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s11095-016-1870-z","article-title":"New perspectives for fixed dose combinations of poorly water-soluble compounds: a case study with ezetimibe and lovastatin","volume":"33","author":"Riekes","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2019.105048_bb0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.xphs.2016.07.009","article-title":"Co-amorphous formation induced by combination of tranilast and diphenhydramine hydrochloride","volume":"106","author":"Ueda","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105048_bb0135","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1211\/jpp.58.8.0007","article-title":"Effects of cranberry juice on nifedipine pharmacokinetics in rats","volume":"58","author":"Uesawa","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2019.105048_bb0140","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1208\/s12249-015-0371-4","article-title":"Co-amorphous combination of nateglinide-metformin hydrochloride for dissolution enhancement","volume":"17","author":"Wairkar","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejps.2019.105048_bb0145","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijpharm.2011.10.053","article-title":"Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes","volume":"422","author":"Yan","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2019.105048_bb0150","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijpharm.2004.07.042","article-title":"Physical properties and dissolution behaviour of nifedipine\/mannitol solid dispersions prepared by hot melt method","volume":"291","author":"Zajc","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2019.105048_bb0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1208\/s12248-010-9185-1","article-title":"DDSolver: an add-in program for modeling and comparison of drug dissolution profiles","volume":"12","author":"Zhang","year":"2010","journal-title":"AAPS J."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719303197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719303197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T02:04:51Z","timestamp":1568426691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098719303197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":30,"alternative-id":["S0928098719303197"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105048","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co amorphous valsartan nifedipine system: Preparation, characterization, in vitro and in vivo evaluation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105048"}}